Endocrine Abstracts

Background: Alpelisib is a novel phosphotidylinositol 3-kinase (PI3K) inhibitor which, in combination with fulvestrant, has been shown to increase progression-free survival in patients with HR+/HER2-/PI3KCA mutated advanced breast cancer[1]. Hyperglycaemia, including alpelisib-induced diabetic ketoacidosis is a known adverse effect, along with rash, diarrhoea and stomatitis. No other associated endocrinopathy has been reported to date. Case presentation: We present th...